With a virtual USD 100,000 RITA has created a portfolio of investments in early-stage bioscience companies which were selected because their science was interesting. They were not evaluated by professional investors. All of the [important] criteria they consider, e.g., quality of management, intellectual property, market size, were not computed in our selection. We chose to make [virtual] investments in these companies because their science was fascinating. RITA is a resource for scientists.
You need to upgrade your Flash Player
Value and percent of overall investment per company. Values shown in US dollars.
Ablynx. Brussels-based one-of-a kind camel antibody platform Allos. Small molecule drug with orphan status for T cell lymphomas and Goldman Sachs investment Alnylam. Most complete IP portfolio in the RNA interference space Ariad. Small molecule inhibitor of mTOR for cancer ArQule. Small molecule against promising c-Met cancer target. Biocryst. Peramivir is antiviral for bird flu; small molecule anti-purinogenic drug platform with orphan status for cutaneous T cell lymphoma Cardium. Portfolio of cooling medical device and gene therapies for nonhealing ulcers and post-MI Rx Genvec. Adenovirus vector platform for pancreatic and esophageal cancer and for macular degeneration; also HIV vaccine program funded by NIH Oncolytics. Canadian platform for viral treatment of cancer Osmetech. Microfluidics platform for diagnostics with considerable IP Protalix. Recombinant protein expression system in plants Rosetta. Israeli microRNA platform for drug discovery and diagnostics Silence. RNAi preclinical drug development
Have positions in ARIA ARQL. Currently investing in SPPI CALP VICL. Bargains galore at the moment. One CEO, when I told him I could not understand share price, told me shareholders not interested in R&D they want cash and income.
Found a small adult stem cell biotech with market value $9 million and $34 million in cash. They have very interesting technology. I think stem cels are due for recognition - have investments in GERN and STEM.l
Sort by date